Filing Flows › Anika Therapeutics (ANIK) › Q1 2025
Anika Therapeutics (ANIK) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Anika Therapeutics (ANIK) reported revenue of $26.2M for the first quarter 2025 (Q1 2025), -10% from a year earlier. Operating margin was -16.4%, net loss $4.9M (18.6% of revenue).
Anika Therapeutics, Q1 2025: revenue $26.2M (-10% year over year), operating margin -16.4%, net loss $4.9M, operating cash flow −$130K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.2M | — | -10% |
| Operating profit | −$4.3M | — | — |
| Net earnings | −$4.9M | — | — |
| Operating cash flow | −$130K | — | — |
What changed
Revenue was $26.2M in Q1 2025, down 10% year over year. OEM Channel was the largest line at 57% of revenue. OEM Channel lost $4.5M year over year (down 23%), 159% of the total change.
Gross margin was 56.1%, down 9.3 points from a year earlier. Operating costs exceeded revenue by $4.3M, an operating margin of -16.4%. Operating expenses fell 12% while revenue fell 10%. The quarter ended with a net loss of $4.9M.
Operating cash flow was −$130K. Non-cash charges added back $1.4M of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items added $497K. Capital expenditures of $2.8M exceeded it, leaving free cash flow of −$3.0M.
Questions
What was Anika Therapeutics' revenue in the first quarter 2025?
Anika Therapeutics (ANIK) reported revenue of $26.2M for the first quarter 2025 (Q1 2025), -10% from a year earlier.
Was Anika Therapeutics profitable in the first quarter 2025?
Operating loss was $4.3M (-16.4% of revenue) and net loss $4.9M.
Source: Anika Therapeutics 10-Q on SEC EDGAR.